Hanada S, Kinbara T, Aoki K, Yasui Y, Ikuta K, Manzai M, Mizuno K, Yagami Y, Sakaida H, Okumura Y
Department of Obstetrics and Gynecology, Nagoya City University Medical School.
Jpn J Antibiot. 1989 Oct;42(10):2098-106.
Pharmacokinetic and clinical studies on a new cephalosporin antibiotic, cefodizime (THR-221, CDZM), were performed and the results obtained are summarized as follows: 1. At about 84 minutes after a bolus injection of 1 g dose of CDZM, the drug was transferred well into tissues of internal genital organs and remained there at therapeutic levels for 285 minutes. The drug was also transferred quickly and sufficiently into exudate from pelvic dead space and its levels were still kept at high levels at 6 hours after administration. 2. CDZM was given to 8 women affected with gynecologic infections. The outcome of CDZM therapies showed that the drug was effective in all 8 of patients (100%) clinically and bacteriologically. 3. Notable adverse effects or abnormal laboratory test results were not observed except for 2 patients with transient and slight elevation of transaminase levels. Based on these results, it may be concluded that CDZM is a highly effective and a very safe antibiotic for the treatment on infectious diseases in gynecologic field.
对一种新型头孢菌素抗生素头孢地嗪（THR - 221，CDZM）进行了药代动力学和临床研究，所得结果总结如下：1. 在静脉推注1g剂量的CDZM后约84分钟，药物能很好地转移至内生殖器官组织，并在治疗水平维持285分钟。药物也能快速充分地转移至盆腔死腔的渗出液中，给药6小时后其水平仍维持在较高水平。2. 对8名患有妇科感染的女性给予CDZM治疗。CDZM治疗结果显示，该药物在所有8例患者中临床和细菌学上均有效（100%）。3. 除2例患者转氨酶水平有短暂轻微升高外，未观察到明显不良反应或异常实验室检查结果。基于这些结果，可以得出结论，CDZM是治疗妇科领域传染病的一种高效且非常安全的抗生素。
